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NOTES AND COMMENTS 
Cycling of antibiotics: an approach to circumvent 
resistance in specialized units of the hospital 
There is a natural cyclic nature to antibiotic resistance 
(Figure 1). New compounds are introduced into 
clinical medicine and their initial successful use often 
leads to overuse. Once a critical mass of compound has 
been used, resistance to the drug begins to emerge. 
This can result from the influx of new species that are 
intrinsically resistant to the drug or from the acquisition 
of resistance among initially susceptible strains. Once 
resistance to a given agent rises to a critical level, use is 
abandoned in favor of yet another new compound. 
This cycle has been repeated nunierous times during 
the antibiotic era. Until the present time, the prevailing 
belief has been that the cycle will never be broken 
because the pharmaceutical industry will always 
provide new compounds which will be effective against 
the strains that have become resistant to previously used 
drugs. 
There are many examples of this emergence of 
antibiotic resistance. The overuse of glycopeptides has 
led to the emergence of vanconiycin-resistant entero- 
cocci. So great was the selective pressure that this 
organism was forced to acquire multiple new genes, 
altering cell wall biosynthesis, in order to survive in the 
environment where vanconiycin was being used 
injudiciously both orally and parenterally. Overuse of 
the fluoroquinolones quickly led to the emergence of 
resistant strains among staphylococci. In certain US 
hospitals within one year of the introduction of the 
fluoroquinolones, the majority of strains of methicillin- 
resistant staphylococci were resistant to this drug class, 
whereas prior to their introduction, resistance had been 
exceedingly rare. The ease with which the staphylo- 
cocci developed resistance to the fluoroquinolones 
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reflects the fact that one mutation in a chromosonial 
gene involving the drug target changed these mar- 
ginally susceptible organisms to resistant organisms in a 
single step. Overuse of the cephalosporins, especially 
the later-generation cephalosporins, has been accon- 
panied by increasing prevalence of resistance among 
both Gram-positive and Gram-negative bacteria. Peni- 
cillin-resistant pneumococci and methicillin-resistant 
staphylococci have become quite prevalent in popu- 
lations where oral cephalosporins are frequently uscd. 
Among Gram-negative bacteria, resistance resulting 
from expression of high levels of various p-lactaniases 
and/or production of mutant enzynies (such as 
extended-spectrum P-lactamases and inhibitor-resistant 
TEM P-lactamases) has become problematic in many 
environments where later-generation cephalosporins 
have been overused. 
Can one control these emerging populations of 
ever more resistant organisms? Strong evidence exists 
that strict adherence to proven infection control pro- 
cedures can prevent nosocomial outbreaks with these 
organisms. However, infection control practitioners 
must be ever vigilant that these procedures are being 
followed consistently and that multiresistant Grain- 
negative bacilli are viewed with the same concern as 
methicillin-resistant staphylococci have always been. 
More attention needs to be paid to which disinfectant 
is being used in an environment. Disinfectants adequate 
for Gram-negatives are often inadequate for Grani- 
positives, especially the enterococci. In the face of 
present problems, the use of oral vanconiycin should be 
avoided whenever possible, and metronidazole substi- 
tuted for documented CIostvidiuln d@ik enterocolitis. 
The current practice of administering oral vancornycin 
for every patient even vaguely suspected of having this 
problem must be abandoned. Use of non-systemic or 
weakly active fluoroquinolones for any purpose should 
be avoided as well. This will eliminate the selective 
pressure favoring survival of single-step niutants with 
altered DNA gyrase or fluoroquinolone inipernie- 
ability among the normal flora as well as in the 
pathogen under treatment. 
Can anything else be done? Clearly, up to this 
point in time, the cycle has been driven by resistance, 
i.e. the wheel has turned when resistance has become 
too prevalent. Should it not be possible to gain control 
of the wheel and turn it before resistance dictates? Why 
not control use of an antibiotic in a given environment 
and rotate to a new compound before resistance 
becomes a problem, i.e. why not cycle antibiotics? In 
hospitals today, with ever-advancing technology, patients Figure 1 The cyclic nature of antibiotic retistance. 
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are surviving diseases and traumatic catastrophes that 
were previously uniformly fatal. Such advances have 
left us with a clustering of patients in special care units 
who are destined to spend prolonged and/or repeated 
intervals in the hospital. The intensive care units, 
hematology/oncology units, burn units, trauma centers 
and transplantation centers are examples of such special 
care units. In these units there is a concentration of 
patients at high risk of serious infection, and antibiotics 
must be utilized empirically at the first sign of potential 
problems. Withholding of antibiotics is not an option 
for controlling the total mass of drug used in these 
specialized environments. Nor are discharging the 
patient or transfer to another area of the hospital viable 
options in many instances. In these specialized environ- 
ments, perhaps the cycling of antibiotics used during 
the empirical stage of therapy would help to diminish 
the emergence of resistance. 
An example of such a cycling scheme is shown in 
Figure 2, where p-lactam antibiotics with or without 
an aminoglycoside are cycled every 2 months for 
empirical therapy. During the first 2 months of the 
cycle an anti-Gram-negative penicillin with or without 
a P-lactamase inhibitor and with or without an amino- 
glycoside will be used as empirical therapy for all 
patients in the unit requiring such therapy. During the 
second 2 months of the cycle a carbapenem with or 
without an aminoglycoside will be used. During the 
third 2 months, a cephalosporin with or without an 
aminoglycoside will be used. The precise drugs used 
during each phase of the cycle should be tailored to fit 
the needs of the unit. For example, if Psetrdovnonas 
aevcrginosa is a problem organism for the unit, perhaps 
an antipseudomonal penicillin will be preferred for the 
penicillin phase of the cycle while ampicillin may be 
preferred for units with problems with Gram-positive 
organisms. For the cephalosporin phase of the cycle, a 
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Figure 2 Example of a cycling scheme for empirical 
therapy that utilizes P-lactam antibiotics. Each regimen in 
the cycle is continued for 2 months. 
fourth-generation compound like cefepime or cefpi- 
ronie may be preferred if multiresistant Evlterobactev 
species are common. Among third-generation com- 
pounds, ceftazidime should probably be avoided in the 
cycle, since clinical data now show this drug to be more 
likely to select resistance than other third-generation 
drugs. Aminoglycosides may also need to be cycled if 
resistance to one or more of them is prevalent in the 
unit. 
It is important to note that the cycling scheme is 
for empirical therapy only. Once the etiologic agent of 
infection has been identified, the patient must be 
switched to another therapy specifically targeted for the 
pathogen isolated. This specific therapy should differ 
from the regimen being used in the current phase of 
the cycle whenever possible. Mandatory switching to 
specific therapy will also help to diminish overall use of 
each agent in the unit. Although patients with no 
etiologic agent identified would be continued on the 
empirical regimen, any patient on the empirical 
regimen at the time the 2-month phase ends must be 
cycled to the new empirical regimen. This ensures no 
long-term carryover of patients on the previous 
regimen. In the cycle scheme shown in Figure 2, a 
glycopeptide would be restricted for use in patients in 
whom a Gram-positive infection requiring this parti- 
cular class of drug is strongly suspected. Glycopeptide 
usage should be continuously monitored for appro- 
priateness, quantitatively and qualitatively. Fluoro- 
quinolones would be reserved for use in those patients 
who appear to be failing the empirical regimen or who, 
because of toxicity or allergy, cannot be given the 
enipirical regimen. The salient features of a model 
cycling program are listed in Table 1. 
A scheme to cycle antibiotics can consist of any of 
a number of antibiotics. The effectiveness of the entire 
cycle depends upon how diligently it is adhered to, 
appropriateness of the drugs chosen for the specific unit 
in question, and the duration of each phase of the cycle. 
For a p-lactani phase, 2 months was chosen as the 
duration, based upon epidemiologic studies demon- 
strating evolution of resistance in 10 weeks in a special 
care unit that utilized a third-generation cephalosporin 
as exclusive empirical therapy. Were a fluoroquinolone 
to be chosen for a phase of the cycle, 2 months would 
probably be too long, as resistant staphylococci or 
streptococci may become a problem much sooner. 
Cycling of antibiotics to forestall resistance might also 
be effective if, rather than cycling by time interval, 
cycling by patient were done. For example, four 
different empirical regimens could be chosen, and all 
patients admitted to the unit who required empirical 
chemotherapy would be cycled among these regimens. 
Patient 3 would receive regimen 1, patient 2 would 
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Table 1 Salient features of a n  antibiotic cycling program 
1. 
3 -. 
3. 
4. 
5. 
6. 
7 
8 
Kigid enforcement of infection control procedures 
(a) Unannounced inspectioiis for cornpliance 
(b) Sanctions for repeated failure to coniply 
Continued review of appropi-iatencss of disinfectant\ for 
individual  units 
(a) Eliminate oral use 
(b) Adiiiiiiister paretiterally only with strong evidence of nerd in  
individual patients 
(c) Continually monitor qpropriatcness of usc 
Elinmiation of iisc of iiw-systcriuc or weakly .ictivc 
fluoroquiriolonrs for any purpose 
Reservation of systemic fluoroquinolones for individual failures, 
allergy or toxicity of the empirical regiiiieii 
Cycling of three regimens for empirical therapy 
(a) Using each rcgiiiicii 110 longer thdii 2 iiionths 
(b) Avoiding consccutivc reglineris with p-lactmis &om the 
(c) Selecting component regirneiis aiid their order of use on the 
Minimal use of Vdncomycili 
raiiie class, e.g. penicillins or cephalosporins 
basis of prevalence of organisms and resistance mechmisins 
111 iridividual units 
Chitinning coniiiiitiiient from all iiicmbcrs of the Iicalthcdrc 
team i? essential 
Continued monitoring, cducation and rcinforceincnt of go‘ils is 
imperative for s~iccess 
receive regimen 2, patient 3 would receivc regiiiicn 3, 
patient 4 would receive regimen 4, and patient 5 would 
receive regimen 1, and the cycle would then begin 
again. This approach might be effective for srnall units 
where prolonged stays are uncommon. However, i n  
larger units, where prolonged stays are common, this 
patient-based cycling scheme could lead to thc conmiit 
high-level use of a particular agent with recultant 
emergence of resistance. 
The ultimate goal of any cycling scheine is to keep 
the total mass of any drug below the critical level that 
leads to emergence of resistance. Knowledge of the 
genetic bases and iriechanisnis responsible for resistance 
is iiiiperativc in designing an effective scheine. If use of 
any one drug selects for resistance to other agents as 
well as to itself, all drugs selecting for and affected by 
the resistance(s) selected iiiust be ‘rested’ in the next 
phase of the cycle. It  would not be effective, for 
example, to cycle among different advanced-generation 
cephalosporins or among different fluoroquinolones. 
However, since different enzymes impart resistance to 
individual aininoglycosides, it may be possible to cycle 
between ainikacin arid gentamiciii or tobrainycin. In 
the case of genetically linked resistances imparted by 
different mechanisms, all drugs involved must be 
‘rested’. 
There are many possible objections that can be 
raised to any scheme of cycling, not the least of which 
is the absence of data from controlled trials that prove 
its efficacy. Such trials are clearly needed and are 
currently being structured in several locations world- 
wide. Additional objections include practicability and 
cost. Since each hospital should develop a cycling 
scheme that best suits the needs of its own special units, 
practicability should be built into the scheme as it is 
being developed. Practicability should not be confused 
with simplicity or a laissez .faire attitude. Conversely, 
changes in a hospital’s routine that introduce increased 
control over antibiotic use should not be confused with 
impracticability. If cycling can be shown to be eff- 
cacious in reducing resistance, overall costs should 
decrease. In the formula for determining cocts, the cost 
of antibiotic resistance must be factorcd in. Such costs 
have been estimated in the tens of billions of dollars for 
the USA alone. Unlike other hospital costs, the cost of 
antibiotic resistance does not impact solely on the 
patient involved, who is likely to have a longer hospital 
stay and perhaps greater morbidity and mortality. Anti- 
biotic resistance impacts on future patients for months 
and perhaps years to come. The potential economic 
impact can be staggering. 
It  is clear that if the natural cycle for antibiotic 
resistance is allowed to continue, the cycle will coon be 
broken - broken not by the diccovery of a new drug 
that solves the problem of resictance but broken by the 
inability of the pharmaceutical industry to continually 
provide effective new drugs. When that happens, the 
‘post-antibiotic era’ will have begun in earnest. The 
emergence of vancoinycin-resistant enterococci is an 
early example of pathogens of this post antibiotic era - 
pathogens for which there is no longer any effective 
therapy. When this resistance iiiechanism moves into 
the more prevalent and virulent Stapkylomcur a iue i~s ,  ac 
surely it will, there will be an even greater problcni 
pathogen of the post-antibiotic era. Rather than 
awaiting the onset of the post-mtibiotic era, would it 
not be more advantageous to try to wrest control of the 
cycle so that judicious antibiotic use would become the 
driving force rather than antibiotic resistance? 
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